Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Neelam Goyal completed her medical school education at SUNY Downstate in Brooklyn, NY. She then finished her neurology residency including chief year followed by a fellowship year in neurophysiology with a focus on neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital,. After graduation, she joined the faculty of Stanford University School of Medicine in 2012 as a Clinical Assistant Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine. She took on the position of co-Director of the Muscular Dystrophy Association/ALS Clinic in 2016. In 2020, she was promoted to Clinical Associate Professor. She serves on multiple committees within Stanford, including the Clinical Assistant Professor Appointment and Promotions Committee and Health Information Management Committee, as well as multiple committees within the American Association of Neuromuscular and Neurodiagnostic medicine (AANEM).Dr. Goyal specializes in the diagnosis, management, and electrophysiological testing of neuromuscular disorder (including SFEMG), with expertise in immune-mediated disorders (myositis, myasthenia gravis, CIDP, and vasculitis) and ALS. Her research interest include monitoring and management of short and long-term toxicity of immunosuppressive agents. She also provides botulinum toxin for treatment of sialorrhea in ALS patients.
Dr. Goyal specializes in the diagnosis, management, and electrophysiological testing of neuromuscular disorder (including SFEMG), with expertise in immune-mediated disorders (myositis, myasthenia gravis, CIDP, and vasculitis) and ALS. Her research interest include monitoring and managing toxicity of immunosuppressive agents. She is co-director of the MDA clinic, and provides botulinum toxin for treatment of sialorrhea for ALS patients.
An Efficacy and Safety Study of Ravulizumab in ALS Participants
The purpose of the study is to assess the efficacy and safety of ravulizumab for the
treatment of adult participants with ALS.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the
ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG.
Patients who have completed at least 1 cycle of treatment and at least 1 year of trial
ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial
ARGX-113-2002 to receive efgartigimod by SC administration.
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for
the treatment of participants with generalized myasthenia gravis (gMG).
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means
the body makes antibodies that attack its own cells and tissues. These types of antibodies
are also known as autoantibodies. People with generalized myasthenia gravis have a weakness
in many muscles.
TAK-079 is a medicine to help people with generalized myasthenia gravis.
The main aim of this study is to check if people with generalized myasthenia gravis have side
effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical
condition and lowers their autoantibody levels.
At the first visit, the study doctor will check if each person can take part. For those who
can take part, participants will continue with their standard medicines for this condition
during the study. Each participant will have a check-up by the study doctor.
Then, the participants will have 1 of 3 treatments:
- A low dose of TAK-079.
- A high dose of TAK-079.
- A placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in
Participants will not know which treatment they received, nor will their study doctors. This
is to help make sure the results are more reliable.
For each treatment, participants will receive injections just under the skin, once a week for
8 weeks. The study doctors will check for side effects from the study treatments. The study
doctors can stop or delay the injections in each participant if needed.
Then, the study doctors will continue to check for side effects for up to 24 weeks after
treatment. They will also check the clinical condition of the participants, including their